A Phase 1 interventional study of Risankizumab and Risankizumab in Healthy Volunteers, sponsored by AbbVie. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-07.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese participants.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive SC injections of risankizumab at dose A and then followed for 140 days.
Drug: Risankizumab
Participants will receive SC injections of risankizumab at dose B and then followed for 140 days.
Drug: Risankizumab
Participants will receive IV infusion of risankizumab at dose C and then followed for 140 days.
Drug: Risankizumab
Intravenous (IV) Infusion
Also known as: ABBV-066, SKYRIZI
Subcutaneous (SC) Injection
Also known as: ABBV-066, SKYRIZI
Number of Participants with Adverse Events (AE)
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Approximately 140 Days
Maximum Observed Concentration (Cmax)
Maximum observed concentration.
Time frame: Up to Approximately 140 Days
Time to Cmax (Tmax)
Time to Cmax.
Time frame: Up to Approximately 140 Days
Terminal Phase Elimination Rate Constant (β)
Terminal phase elimination rate constant.
Time frame: Up to Approximately 140 Days
Terminal Phase Elimination Half-life (t1/2)
Terminal phase elimination half-life.
Time frame: Up to Approximately 140 Days
Area Under the Concentration-Time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt)
AUC from time 0 to time of the last measurable concentration (AUCt).
Time frame: Up to Approximately 140 Days
AUC from Time 0 to Infinity (AUCinf)
AUC from time 0 to infinity (AUCinf).
Time frame: Up to Approximately 140 Days
Apparent Clearance (CL/F) for Subcutaneous (SC) dosing
CL/F for SC dosing.
Time frame: Up to Approximately 140 Days
Clearance (CL) for Intravenous (IV) Dosing
CL for IV dosing.
Time frame: Up to Approximately 140 Days
Number of Anti-drug antibody (ADA) Titers
ADA titers will be tabulated for each participant at the respective study visits.
Time frame: Up to Approximately 140 Days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2019 to primary completion in Apr 2020, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab